Certified Clinical Research Associate (CCRA) Exam
2026 Latest Comprehensive Study Guide with
Practice Questions, Clinical Trial Management
Review, Detailed Rationales, Verified Answers,
Success Workbook
DOMAIN I: REGULATORY & ETHICAL COMPLIANCE (25-30%)
1. According to ICH GCP E6(R2), what is the primary responsibility of the
Investigator?
A) To ensure the study is conducted in compliance with the protocol and
applicable regulations
B) To monitor the study data for completeness
C) To analyze the study results
D) To provide funding for the study
Answer: A) To ensure the study is conducted in compliance with the
protocol and applicable regulations
Rationale: ICH GCP E6(R2) Section 4.1 states that the Investigator is
responsible for conducting the trial in accordance with the protocol, ICH GCP,
and applicable regulatory requirements. The CRA (not the Investigator) is
responsible for monitoring data (B), the sponsor typically handles data
analysis (C), and funding comes from the sponsor (D).
2. Which document formally authorizes the initiation of a clinical trial at
a specific site?
A) Clinical Trial Agreement
B) IRB Approval Letter
C) FDA Form 1572
D) Investigator's Brochure
Answer: B) IRB Approval Letter
,Rationale: The IRB (or Ethics Committee) approval letter documents that the
IRB has reviewed and approved the study protocol, informed consent form,
and other required documents, formally authorizing site initiation. The
Clinical Trial Agreement (A) is a financial/legal document, the FDA Form 1572
(C) is the investigator's commitment statement, and the Investigator's
Brochure (D) contains drug information.
3. Which of the following is one of the core principles of ICH GCP?
A) Clinical trials should be conducted in compliance with the protocol only
B) The rights, safety, and well-being of trial subjects are the most
important considerations and should prevail over interests of science
and society
C) Financial considerations should take precedence over subject safety
D) Only healthy volunteers may participate in clinical trials
Answer: B) The rights, safety, and well-being of trial subjects are the
most important considerations and should prevail over interests of
science and society
Rationale: This is a fundamental principle of ICH GCP, derived from the
Declaration of Helsinki. Subject protection is paramount. Protocols must be
followed (A), but they are not the only consideration. Financial interests (C)
never supersede subject safety. Healthy volunteers are only used in certain
phases (primarily Phase I) (D).
4. The Declaration of Helsinki addresses which of the following?
A) Financial disclosure requirements for investigators
B) Ethical principles for medical research involving human subjects
C) Good Manufacturing Practices for investigational products
D) Data protection and privacy regulations
Answer: B) Ethical principles for medical research involving human
subjects
Rationale: The Declaration of Helsinki is a statement of ethical principles
developed by the World Medical Association for medical research involving
human subjects. It is a foundational document referenced in ICH GCP.
,5. What is the purpose of FDA Form 1572?
A) To document the sponsor's financial interest in the study
B) To provide the investigator's commitment to comply with FDA
regulations and to disclose information about the investigator and study
site
C) To obtain informed consent from study subjects
D) To report serious adverse events to the FDA
Answer: B) To provide the investigator's commitment to comply with
FDA regulations and to disclose information about the investigator and
study site
Rationale: The FDA Form 1572 is a statement of the Investigator's
commitment to comply with regulations and provides information on the
Investigator, sub-investigators, and study site.
6. Which of the following is NOT a required element of informed consent
according to ICH GCP?
A) A statement that the study involves research
B) A description of any reasonably foreseeable risks or discomforts
C) A guarantee that the subject will benefit from participating in the
study
D) A statement that participation is voluntary
Answer: C) A guarantee that the subject will benefit from participating in
the study
Rationale: Informed consent cannot guarantee benefit; it must accurately
describe the potential risks and benefits. ICH GCP requires that subjects be
informed of the reasonably foreseeable risks, discomforts, and potential
benefits, but a guarantee of benefit is not permitted and would be unethical.
7. Which organization is responsible for protecting the rights and
welfare of human research subjects?
A) The sponsor
, B) The Clinical Research Associate
C) The Institutional Review Board (IRB) / Independent Ethics Committee
(IEC)
D) The Data Safety Monitoring Board
Answer: C) The Institutional Review Board (IRB) / Independent Ethics
Committee (IEC)
Rationale: The IRB/IEC is an independent body established to protect the
rights, safety, and well-being of human subjects involved in research. The
sponsor (A) funds the study, the CRA (B) monitors it, and the DSMB (D)
monitors safety data during the trial.
8. According to ICH GCP, who is ultimately responsible for the conduct of
the trial at a site?
A) The Clinical Research Associate
B) The Investigator
C) The sponsor's project manager
D) The site's research coordinator
Answer: B) The Investigator
Rationale: ICH GCP Section 4.1 clearly states that the Investigator is
responsible for the conduct of the trial at the site. While the CRA monitors (A),
the project manager oversees the study (C), and the coordinator assists (D),
ultimate responsibility rests with the Investigator.
9. What is the purpose of the "Certificate of Confidentiality" issued by the
U.S. government?
A) To certify that the investigator is qualified to conduct the trial
B) To protect the privacy of research subjects by prohibiting disclosure of
identifying information in legal proceedings
C) To verify that the investigational product meets quality standards
D) To confirm that the study site has passed inspection
Answer: B) To protect the privacy of research subjects by prohibiting
disclosure of identifying information in legal proceedings
2026 Latest Comprehensive Study Guide with
Practice Questions, Clinical Trial Management
Review, Detailed Rationales, Verified Answers,
Success Workbook
DOMAIN I: REGULATORY & ETHICAL COMPLIANCE (25-30%)
1. According to ICH GCP E6(R2), what is the primary responsibility of the
Investigator?
A) To ensure the study is conducted in compliance with the protocol and
applicable regulations
B) To monitor the study data for completeness
C) To analyze the study results
D) To provide funding for the study
Answer: A) To ensure the study is conducted in compliance with the
protocol and applicable regulations
Rationale: ICH GCP E6(R2) Section 4.1 states that the Investigator is
responsible for conducting the trial in accordance with the protocol, ICH GCP,
and applicable regulatory requirements. The CRA (not the Investigator) is
responsible for monitoring data (B), the sponsor typically handles data
analysis (C), and funding comes from the sponsor (D).
2. Which document formally authorizes the initiation of a clinical trial at
a specific site?
A) Clinical Trial Agreement
B) IRB Approval Letter
C) FDA Form 1572
D) Investigator's Brochure
Answer: B) IRB Approval Letter
,Rationale: The IRB (or Ethics Committee) approval letter documents that the
IRB has reviewed and approved the study protocol, informed consent form,
and other required documents, formally authorizing site initiation. The
Clinical Trial Agreement (A) is a financial/legal document, the FDA Form 1572
(C) is the investigator's commitment statement, and the Investigator's
Brochure (D) contains drug information.
3. Which of the following is one of the core principles of ICH GCP?
A) Clinical trials should be conducted in compliance with the protocol only
B) The rights, safety, and well-being of trial subjects are the most
important considerations and should prevail over interests of science
and society
C) Financial considerations should take precedence over subject safety
D) Only healthy volunteers may participate in clinical trials
Answer: B) The rights, safety, and well-being of trial subjects are the
most important considerations and should prevail over interests of
science and society
Rationale: This is a fundamental principle of ICH GCP, derived from the
Declaration of Helsinki. Subject protection is paramount. Protocols must be
followed (A), but they are not the only consideration. Financial interests (C)
never supersede subject safety. Healthy volunteers are only used in certain
phases (primarily Phase I) (D).
4. The Declaration of Helsinki addresses which of the following?
A) Financial disclosure requirements for investigators
B) Ethical principles for medical research involving human subjects
C) Good Manufacturing Practices for investigational products
D) Data protection and privacy regulations
Answer: B) Ethical principles for medical research involving human
subjects
Rationale: The Declaration of Helsinki is a statement of ethical principles
developed by the World Medical Association for medical research involving
human subjects. It is a foundational document referenced in ICH GCP.
,5. What is the purpose of FDA Form 1572?
A) To document the sponsor's financial interest in the study
B) To provide the investigator's commitment to comply with FDA
regulations and to disclose information about the investigator and study
site
C) To obtain informed consent from study subjects
D) To report serious adverse events to the FDA
Answer: B) To provide the investigator's commitment to comply with
FDA regulations and to disclose information about the investigator and
study site
Rationale: The FDA Form 1572 is a statement of the Investigator's
commitment to comply with regulations and provides information on the
Investigator, sub-investigators, and study site.
6. Which of the following is NOT a required element of informed consent
according to ICH GCP?
A) A statement that the study involves research
B) A description of any reasonably foreseeable risks or discomforts
C) A guarantee that the subject will benefit from participating in the
study
D) A statement that participation is voluntary
Answer: C) A guarantee that the subject will benefit from participating in
the study
Rationale: Informed consent cannot guarantee benefit; it must accurately
describe the potential risks and benefits. ICH GCP requires that subjects be
informed of the reasonably foreseeable risks, discomforts, and potential
benefits, but a guarantee of benefit is not permitted and would be unethical.
7. Which organization is responsible for protecting the rights and
welfare of human research subjects?
A) The sponsor
, B) The Clinical Research Associate
C) The Institutional Review Board (IRB) / Independent Ethics Committee
(IEC)
D) The Data Safety Monitoring Board
Answer: C) The Institutional Review Board (IRB) / Independent Ethics
Committee (IEC)
Rationale: The IRB/IEC is an independent body established to protect the
rights, safety, and well-being of human subjects involved in research. The
sponsor (A) funds the study, the CRA (B) monitors it, and the DSMB (D)
monitors safety data during the trial.
8. According to ICH GCP, who is ultimately responsible for the conduct of
the trial at a site?
A) The Clinical Research Associate
B) The Investigator
C) The sponsor's project manager
D) The site's research coordinator
Answer: B) The Investigator
Rationale: ICH GCP Section 4.1 clearly states that the Investigator is
responsible for the conduct of the trial at the site. While the CRA monitors (A),
the project manager oversees the study (C), and the coordinator assists (D),
ultimate responsibility rests with the Investigator.
9. What is the purpose of the "Certificate of Confidentiality" issued by the
U.S. government?
A) To certify that the investigator is qualified to conduct the trial
B) To protect the privacy of research subjects by prohibiting disclosure of
identifying information in legal proceedings
C) To verify that the investigational product meets quality standards
D) To confirm that the study site has passed inspection
Answer: B) To protect the privacy of research subjects by prohibiting
disclosure of identifying information in legal proceedings
